Malachite Innovations Retains Investment Banking Firm to Assist in Implementation of Strategic Plan for Cannabinoid Drug Development Business
CLEVELAND, OHIO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) (“Malachite”) announces that it has retained First Liberties Securities, Inc., d/b/a First Liberties Financial (“FLF”), a registered broker-dealer headquartered in Dallas, Texas, to assist Malachite in the implementation of its strategic plan for its cannabinoid drug development business conducted by its wholly-owned subsidiary, Graphium Biosciences, Inc. (“Graphium”), which may include converting Graphium into a separate and distinct privately held company funded with new capital.
- In 2021, Malachite initiated a corporate restructuring plan to create two parallel pathways for shareholder value creation and optimize the present value of its more than $20 million of net operating losses.
- Additionally, Graphium has expanded its drug development partnerships with advisors and manufacturers in Australia, and created a detailed and executable drug development plan to advance its leading cannabinoid compound, VBX-100, through Phase II clinical trials over the next three years, subject to securing the necessary funding.
- Malachite is seeking to raise up to $4.0 million directly into Graphium (“Capital Raise”) to fund the advancement of its cannabinoid drug development program and for general working capital purposes.
- We will initially continue our focus on advancing VBX-100, a uniquely non-psychoactive cannabinoid therapeutic, but also continue innovating and developing the hundreds of additional small molecules in our broad portfolio of cannabinoid drug assets.”